Moderna raised its 2026 revenue growth outlook on Friday after beating third-quarter revenue and earnings estimates. The company now expects revenue growth of 15% to 25%, up from its previous guidance of up to 10%. Shares rose roughly 3% in premarket trading.
Third-quarter revenue jumped 29% to $1.31 billion. U.S. revenue was $780 million and international revenue was $533 million. The company reported net income of $162 million, or 38 cents per share, compared with a net loss of $200 million, or 51 cents per share, a year earlier.
CEO Stéphane Bancel credited newer products and geographic expansion for the results. He said Moderna is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. He said the company's new stand-alone flu shot, approved in the U.S. in August, will have a "limited launch" in the country in 2026 because of timing. Bancel also said expansion in Canada, the U.K. and Asia helped boost results, and that lower costs contributed to the profit. "It's the sales that are stronger and the costs that are also lower," he said.
Bancel described the stock's reaction to recent cancer vaccine data as a "surprising reaction." Moderna and Merck unveiled late-stage data on an experimental personalized cancer vaccine combined with Keytruda in certain melanoma patients. Part of the data was leaked on social media days before trial investigators were set to present it at a European medical conference, and investors sold the stock. Bancel said long-term investors and analysts who reviewed the full data responded positively, and that doctors "were so impressed with the data."
Moderna's stock has risen more than 700% this year, which the report attributes largely to optimism about the cancer vaccine.